Assessment of reflux symptom severity: Methodological options and their attributes

Gut

Volumn 53, Issue SUPPL. 4, 2004, Pages

  Bytzer, P ^a  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ESOMEPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY; VALIDATION PROCESS;

CHRONIC DISEASE; CLINICAL TRIALS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; PAIN MEASUREMENT; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 2342597763     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.034298     Document Type: Review

References (48)

1. Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:1023-9.
2. Carlsson R, Bolling E, Jerndal P, et al. Factors predicting response to omeprazole treatment in patients with functional dyspepsia. Gastroenterology 1996;110:A76.3.
3. Carlsson R, Frison L, Lundell L, et al. Relationship between symptoms, endoscopic findings and treatment outcome in reflux esophagitis. Gastroenterology 1996;110:A77.
4. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-9.
5. Galmiche J-P, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997;11:765-73.
6. Carlsson R, Dent J, Watts DA, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998;10:119-24.
7. Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-73.
8. Bate CM, Griffin SM, Keeling PWN, et al. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996;10:547-55.
9. Talley NJ, Venables TL, Green JBR, et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placeba-controlled trial of "on-demand" therapy for 6 months. Gastroenterology 2000;118:A658.
10. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000;14:1249-58.
11. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety at esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-65.
12. Veldhuyzen van Zanten SJO, Tytgat KMAJ, Pollak PT, et al. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol 1993;46:273-9.
13. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83.
14. Johnson DA, Benjamin S, Vakil N, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esopnagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001;96:27-34.
15. Havelund T, Aalykke C. The efficacy of a peptic-based raft-forming anti-reflux agent in endoscopy-negative reflux disease. Scand J Gastroenterol 1997;32:773-7.
16. Nyrén O, Adami HO, Bates S, et al. Self-rating of pain in nonulcer dyspepsia. A methodological study comparing a new fixed-point scale and the visual analogue scale. J Clin Gastroenterol 1987;9:408-14.
17. Guyatt G, Berman LB, Townsend M, et al. Should study subjects see their previous responses? J Chronic Dis 1985;38:1003-7.
18. Johnston F, Hatlebakk JG, Klintenberg A-C, et al. The symptom relieving effect of esomeprazole 40 mg daily in patients with heartburn. Gastroenterology 2001;120:A437.
19. Joelsson B, Johnsson F. Heartburn - the acid test. Gut 1989;30:1523-5.
20. Vigneri S, Termini R, Leandra G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-10.
21. Oliveria SA, Christos PJ, Talley NJ, et al. Heartburn risk factors, knowledge, and prevention strategies: a population-based survey of individuals with heartburn. Arch Intern Med 1999;159:1592-8.
22. Dent J, Armstrong D, Delaney B, et al. Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. Gut 2004;53(suppl IV):iv1-24.
23. Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988;23:625-32.
24. Junghard O, Carlsson R, Lind T. Sufficient control of heartburn in endoscopy negative GORD trials. Scand J Gastroenterol 2003;38:1197-9.
25. Talley NJ, Nyrén O, Drossman DA, et al. The irritable bowel syndrome: toward optimal design of controlled treatment trials. Gastroenterol Int 1993;6:189-211.
26. Venables TL, Newland RD, Patel AC, et al. Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol 1997;32:627-32.
27. Hatlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treament in primary care: randomised, double blind study for 8 weeks. BMJ 1999;319:550-3.
28. Johnsson F, Moum B, Vilien M, et al. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol 2002;37:642-7.
29. Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophogitis. Arch Intern Med 2000;160:1810-16.
30. Miner P jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002;97:1332-9.
31. MacKenzie CR, Charlson ME. Standards for the use of ordinal scales in clinical trials. BMJ 1986;292:40-3.
32. Schwizer W, Thumshim M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001;357:1738-42.
33. Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the omeprazole test in patients with symptom suggestive of gastroesophageal reflux disease. Arch Intern Med 1999;159:2161-8.
34. Hungin APS, Rubin G, O'Flanagan H. Factors influencing compliance in long-term proton pump inhibitor therapy in general practice. Br J Gen Pract 1999;49:463-4.
35. Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis - a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999;13:907-14.
36. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months. Aliment Pharmacol Ther 2001;15:347-54.
37. Schindlbeck NE, Klauser AG, Berghammer G, et al. Three year follow up of patients with gastrooesophageal reflux disease. Gut 1992;33:1016-19.
38. Revicki DA, Crawley JA, Zodet MW, et al. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:1621-30.
39. Galmiche J-P, Shi G, Simon B, et al. On-demand treatment of gastro-oesophageal reflux symptoms: a comparison of ranitidine 75 mg with cimetidine 200 mg or placebo. Aliment Pharmacol Ther 1998;12:909-17.
40. Faaij RA, van Gerven JMA, Jolivet-Landreau I, et al. Onset of action during on-demand treatment with Maalox suspension or low-dose ranitidine for heartburn. Aliment Pharmacol Ther 1999;13:1605-10.
41. Holtmann G, Bytzer P, Metz M, et al. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:479-85.
42. Robinson M, Fitzgerald S, Hegedus R, et al. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002;16:445-54.
43. Johnsson F, Weywadt L, Solhaug J-H, et al. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1998;33:15-20.
44. Bate CM, Riley SA, Chapman RWG, et al. Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999;13:59-66.
45. Brun J, Sorngard H. High dose proton pump inhibitor response as an initial strategy for a clinical diagnosis of gastro-esophageal reflux disease (GERD). Fam Pract 2000;17:401-4.
46. Elm M, Hellke P, Andrén K, et al. Time to relief of episodic symptoms of gastro-oesophageal reflux disease. A crossover comparison of single doses of the effervescent and standard formulations of ranitidine. Scand J Gastroenterol 1998;33:900-4.
47. Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000;160:1803-9.
48. Richter JE, Kovacs TO, Greski-Rose PA, et al. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999;13:795-804.